Edgewise Therapeutics CFO sells 4,442 shares for taxes

The share sale covered minimum statutory tax withholding and was described as not discretionary.

Available on EDGAR 11/10/2026 - 05:22 PM EST Accepted by SEC EDGAR 11/10/2026 - 05:21 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. Chief Financial Officer Michael Nofi had 10,937 restricted stock units convert into 10,937 common shares on November 10, 2026; the reported post-transaction RSU balance was 32,813. He sold 4,442 shares at an average price of $45.427 per share to cover minimum statutory tax withholding. The sale was described as not discretionary, and no Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Nofi Michael

Role Chief Financial Officer

Sold 4,442 shs ($202K)

Approx. gross sale proceeds $202K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F3	10,937	$0.00	$0.00
Exercise	Common Stock	10,937	$0.00	$0.00
Sale	Common Stock F1, F2	4,442	$45.427	$202K

Holdings After Transaction: Restricted Stock Units — 32,813 units (Direct); Common Stock — 6,495 shares (Direct)

Footnotes (3)

1. F1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
2. F2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.

Key Figures

Restricted stock units converted: 10,937 RSUs Common shares acquired: 10,937 shares Common shares sold: 4,442 shares +2 more

5 metrics

Restricted stock units converted 10,937 RSUs November 10, 2026

Common shares acquired 10,937 shares Upon conversion of the restricted stock units on November 10, 2026

Common shares sold 4,442 shares November 10, 2026; sold to cover statutory tax withholding

Average sale price $45.427 per share Sale of 4,442 shares on November 10, 2026

RSUs after transaction 32,813 RSUs Reported after the November 10, 2026 transaction

Key Terms

Restricted Stock Units, statutory tax withholding obligations, sell-to-cover, contingent right

4 terms

Restricted Stock Units financial

"Restricted Stock Units ("RSUs") granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

statutory tax withholding obligations financial

"shares sold to cover the statutory tax withholding obligations"

sell-to-cover financial

"funded by a "sell-to-cover" transaction"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

contingent right technical

"each of which represent a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EWTX shares did Michael Nofi sell, and at what price?

Michael Nofi sold 4,442 shares on November 10, 2026, at an average price of $45.427 per share. The shares were sold in multiple transactions at prices ranging from $45.165 to $45.57.

Why did Michael Nofi sell EWTX shares?

The 4,442-share sale covered minimum statutory tax withholding obligations in connection with the vesting of restricted stock units. The sale was described as not discretionary, and no Rule 10b5-1 plan is reported.

What were the terms of Michael Nofi's EWTX restricted stock units?

The restricted stock units were granted for no additional cash consideration, and each represented a contingent right to receive one common share upon vesting. They vest in four equal annual installments beginning November 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nofi Michael

(Last) (First) (Middle)

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2026		M		10,937	A	$0.00	10,937	D
Common Stock	11/10/2026		S		4,442(1)	D	$45.427(2)	6,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	11/10/2026		M			10,937	(3)	11/10/2035	Common Stock	10,937	$0.00	32,813	D

Explanation of Responses:

1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Michael Nofi	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)